Abstract

Microaneurysms (MAs) with hyperreflective rings are sometimes detected in eyes with refractory macular edema (ME) associated with branch retinal vein occlusion (BRVO) for more than 12 months after onset when examined using optical coherence tomography (OCT). We proposed that these MAs could result in refractory ME secondary to BRVO and hypothesized that OCT-guided direct photocoagulation of MAs could result in a reduction in refractory ME. Eleven eyes (from eleven different patients) with refractory ME associated with BRVO for more than 12 months following initial treatment were included. The mean number of MAs in each eye at baseline was 3.5 ± 2.0 (range, 1–8). The mean central subfield thickness, central macular volume, and parafoveal macular volume significantly decreased 6 months following initial direct photocoagulation when compared with those at baseline (baseline = 378.7 ± 61.8 μm, post-treatment = 304.2 ± 66.7 μm, p = 0.0005; baseline = 0.3 ± 0.049 mm3, post-treatment = 0.24 ± 0.053 mm3, p = 0.001; and baseline = 2.5 ± 0.14 mm3, post-treatment = 2.28 ± 0.15 mm3, p = 0.001, respectively). Moreover, the mean best-corrected visual acuity significantly improved 6 months following initial direct photocoagulation when compared with that at baseline (baseline = 0.096 ± 0.2 logarithm of the minimum angle of resolution (logMAR), post-treatment = 0.0077 ± 0.14 logMAR, p = 0.031). Direct photocoagulation could be suggested as a treatment option for refractory ME associated with BRVO in MAs with a hyperreflective ring on OCT.

Highlights

  • Macular edema (ME) is the leading cause of vision loss associated with branch retinal vein occlusion (BRVO) [1,2,3]

  • We demonstrated that optical coherence tomography (OCT)-guided direct photocoagulation for MAs was effective in eyes with refractory ME associated with BRVO

  • At 3 months following initial direct photocoagulation for MAs with a hyperreflective ring on the OCT images, the central subfield thickness (CST), Central macular volume (CMV), and parafoveal macular volume (PFMV) significantly decreased from the baseline, and the effect was maintained for at least 6 months following the procedure

Read more

Summary

Introduction

Macular edema (ME) is the leading cause of vision loss associated with branch retinal vein occlusion (BRVO) [1,2,3]. The efficacy of anti-vascular endothelial growth factor (anti-VEGF) drugs for ME secondary to BRVO has been reported [4,5,6]; despite patients receiving multiple intravitreal injections of anti-VEGF drugs, ME persists for over 1 year following treatment [7,8]. Retinal vascular abnormalities, such as microaneurysms (MAs) [9,10], can develop in the chronic phase of BRVO. Recently, focal/grid laser photocoagulation has been performed without FA guidance [11,12]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.